Table 3.
Resection rate and R0 resection after neoadjuvant therapy in pancreatic cancer
| Group | Resection rate | R0 resected |
|---|---|---|
| Total [95% CI] |
57.7% [49.5,65.5] I 2 = 45.8% (n = 39) |
84.2% [80.1,87.5] I 2 = 27.8% (n = 36) |
| Resectable [95% CI] |
73.0% [64.8,79.9] I 2 = 40.7% (n = 14) |
88.2% [82.1,92.5] I 2 = 34.2% (n = 12) |
| Borderline resectable [95% CI] |
40.2% [28.3,53.4] I 2 = 45.8% (n = 19) |
79.4% [72.2,85.0] I 2 = 16.9% (n = 18) |
| Gemcitabine monotherapy [95% CI] |
67.2% [43.3,84.6] I 2 = 46.7% (n = 6) |
91.7% [80.2,96.8] I 2 = 39.8% (n = 6) |
| Non‐gemcitabine monotherapy [95% CI] |
48.5% [26.3,71.3] I 2 = 45.4% (n = 4) |
86.4% [74.5,93.2] I 2 = 0.0% (n = 3) |
| Combination therapy [95% CI] |
55.6% [44.9,65.8] I 2 = 46.0% (n = 26) |
80.5% [75.5,84.7] I 2 = 17.8% (n = 24) |
| Gemcitabine‐based [95% CI] |
61.1% [51.1,70.2] I 2 = 45.9% (n = 28) |
84.0% [78.7,88.1] I 2 = 33.5% (n = 26) |
| Non‐gemcitabine‐based [95% CI] |
42.0% [23.2,63.4] I 2 = 46.2% (n = 8) |
84.7% [76.0,90.7] I 2 = 0.0% (n = 7) |
| Chemotherapy [95% CI] |
62.9% [45.6,77.4] I 2 = 45.8% (n = 9) |
75.3% [68.6,80.9] I 2 = 7.3% (n = 9) |
| Chemo + radiotherapy [95% CI] |
55.1% [45.4,64.4] I 2 = 45.9% (n = 29) |
86.5% [82.2,90.0] I 2 = 23.8% (n = 26) |